2 May 2018 in Human Brain Mapping
The BrainMap database is a community resource that curates peer‐reviewed, coordinate‐based human neuroimaging literature. By pairing the results of neuroimaging studies with their relevant meta‐data, BrainMap facilitates coordinate‐based meta‐analysis (CBMA) of the neuroimaging literature en masse or at the level of experimental paradigm, clinical disease, or anatomic location. Initially dedicated to the functional, task‐activation literature, BrainMap is now expanding to include voxel‐based morphometry (VBM) studies in a separate sector, titled: BrainMap VBM. VBM is a whole‐brain, voxel‐wise method that measures significant structural differences between or within groups which are reported as standardized, peak x–y–z coordinates. Here we describe BrainMap VBM, including the meta‐data structure, current data volume, and automated reverse inference functions (region‐to‐disease profile) of this new community resource. CBMA offers a robust methodology for retaining true‐positive and excluding false‐positive findings across studies in the VBM literature. As with BrainMap's functional database, BrainMap VBM may be synthesized en masse or at the level of clinical disease or anatomic location. As a use‐case scenario for BrainMap VBM, we illustrate a trans‐diagnostic data‐mining procedure wherein we explore the underlying network structure of 2,002 experiments representing over 53,000 subjects through independent components analysis (ICA). To reduce data‐redundancy effects inherent to any database, we demonstrate two data‐filtering approaches that proved helpful to ICA. Finally, we apply hierarchical clustering analysis (HCA) to measure network‐ and disease‐specificity. This procedure distinguished psychiatric from neurological diseases. We invite the neuroscientific community to further exploit BrainMap VBM with other modeling approaches.
21 December 2020 in Cerebral Cortex
Memory deficits are observed in a range of psychiatric disorders, but it is unclear whether memory deficits arise from a shared brain correlate across disorders or from various dysfunctions unique to each disorder. Connectome-based predictive modeling is a computational method that captures individual differences in functional connectomes associated with behavioral phenotypes such as memory. We used publicly available task-based functional MRI data from patients with schizophrenia (n = 33), bipolar disorder (n = 34), attention deficit hyper-activity disorder (n = 32), and healthy controls (n = 73) to model the macroscale brain networks associated with working, short- and long-term memory. First, we use 10-fold and leave-group-out analyses to demonstrate that the same macroscale brain networks subserve memory across diagnostic groups and that individual differences in memory performance are related to individual differences within networks distributed throughout the brain, including the subcortex, default mode network, limbic network, and cerebellum. Next, we show that diagnostic groups are associated with significant differences in whole-brain functional connectivity that are distinct from the predictive models of memory. Finally, we show that models trained on the transdiagnostic sample generalize to novel, healthy participants (n = 515) from the Human Connectome Project. These results suggest that despite significant differences in whole-brain patterns of functional connectivity between diagnostic groups, the core macroscale brain networks that subserve memory are shared.
1 January 2015 in NeuroImage: Clinical
Noninvasive markers of brain function could yield biomarkers in many neurological disorders. Disease models constrained by coordinate-based meta-analysis are likely to increase this yield. Here, we evaluate a thalamic model of temporal lobe epilepsy that we proposed in a coordinate-based meta-analysis and extended in a diffusion tractography study of an independent patient population. Specifically, we evaluated whether thalamic functional connectivity (resting-state fMRI-BOLD) with temporal lobe areas can predict seizure onset laterality, as established with intracranial EEG. Twenty-four lesional and non-lesional temporal lobe epilepsy patients were studied. No significant differences in functional connection strength in patient and control groups were observed with Mann-Whitney Tests (corrected for multiple comparisons). Notwithstanding the lack of group differences, individual patient difference scores (from control mean connection strength) successfully predicted seizure onset zone as shown in ROC curves: discriminant analysis (two-dimensional) predicted seizure onset zone with 85% sensitivity and 91% specificity; logistic regression (four-dimensional) achieved 86% sensitivity and 100% specificity. The strongest markers in both analyses were left thalamo-hippocampal and right thalamo-entorhinal cortex functional connection strength. Thus, this study shows that thalamic functional connections are sensitive and specific markers of seizure onset laterality in individual temporal lobe epilepsy patients. This study also advances an overall strategy for the programmatic development of neuroimaging biomarkers in clinical and genetic populations: a disease model informed by coordinate-based meta-analysis was used to anatomically constrain individual patient analyses.
9 September 2021 in Frontiers in Psychiatry
Why is psychiatry unable to define clinically useful biomarkers? We explore this question from the vantage of data and decision science and consider biomarkers as a form of phenotypic data that resolves a well-defined clinical decision. We introduce a framework that systematizes different forms of phenotypic data and further introduce the concept of decision model to describe the strategies a clinician uses to seek out, combine, and act on clinical data. Though many medical specialties rely on quantitative clinical data and operationalized decision models, we observe that, in psychiatry, clinical data are gathered and used in idiosyncratic decision models that exist solely in the clinician's mind and therefore are outside empirical evaluation. This, we argue, is a fundamental reason why psychiatry is unable to define clinically useful biomarkers: because psychiatry does not currently quantify clinical data, decision models cannot be operationalized and, in the absence of an operationalized decision model, it is impossible to define how a biomarker might be of use. Here, psychiatry might benefit from digital technologies that have recently emerged specifically to quantify clinically relevant facets of human behavior. We propose that digital tools might help psychiatry in two ways: first, by quantifying data already present in the standard clinical interaction and by allowing decision models to be operationalized and evaluated; second, by testing whether new forms of data might have value within an operationalized decision model. We reference successes from other medical specialties to illustrate how quantitative data and operationalized decision models improve patient care.